中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents

文献类型:期刊论文

作者Li B(李本) ; JONES ERIC DALE ; ZHOU ENKUN ; LI CHEN ; BAYLIS DEAN CAMERON ; Yu SH(余尚海) ; Wang M(汪淼) ; HE XING ; COATES JONATHAN ALAN VICTOR ; RHODES DAVID IAN ; Pei G(裴刚) ; DEADMAN JOHN JOSEPH ; Xie X(谢欣) ; Ma DW(马大为)
刊名Bioorg. Med. Chem. Lett.
出版日期2010
卷号20期号:14页码:4012-4014
ISSN号0960-894X
其他题名含1,3,3,4-四取代吡咯烷的CCR5受体拮抗剂的构效关系研究, 第一部分: N-取代基的调整
通讯作者DEADMAN JOHN JOSEPH ; 谢欣 ; 马大为
英文摘要A novel series of CCR5 antagonists has been identified, utilizing the lead, nifeviroc, which were further modified based on bioisosteric principles. Lead optimization was pursued by balancing potential toxicity and potency. Potent analogues with low toxic properties were successfully developed by formation of urea and amide bonds at the nitrogen at position 4- of the pyrrolidine ring. (C) 2010 Elsevier Ltd. All rights reserved.
学科主题生命有机化学
收录类别SCI
原文出处http://dx.doi.org/10.1016/j.bmcl.2010.05.102
语种英语
WOS记录号WOS:000279258800002
公开日期2013-02-19
源URL[http://202.127.28.38/handle/331003/15645]  
专题上海有机化学研究所_生命有机化学国家重点实验室
推荐引用方式
GB/T 7714
Li B,JONES ERIC DALE,ZHOU ENKUN,et al. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents[J]. Bioorg. Med. Chem. Lett.,2010,20(14):4012-4014.
APA 李本.,JONES ERIC DALE.,ZHOU ENKUN.,LI CHEN.,BAYLIS DEAN CAMERON.,...&马大为.(2010).Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents.Bioorg. Med. Chem. Lett.,20(14),4012-4014.
MLA 李本,et al."Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents".Bioorg. Med. Chem. Lett. 20.14(2010):4012-4014.

入库方式: OAI收割

来源:上海有机化学研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。